JP2002544167A - 有機化合物 - Google Patents
有機化合物Info
- Publication number
- JP2002544167A JP2002544167A JP2000616798A JP2000616798A JP2002544167A JP 2002544167 A JP2002544167 A JP 2002544167A JP 2000616798 A JP2000616798 A JP 2000616798A JP 2000616798 A JP2000616798 A JP 2000616798A JP 2002544167 A JP2002544167 A JP 2002544167A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- xenograft
- rejection
- recipient
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 48
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 40
- 238000013518 transcription Methods 0.000 claims abstract description 27
- 230000035897 transcription Effects 0.000 claims abstract description 27
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 26
- 239000003112 inhibitor Substances 0.000 claims abstract description 25
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 21
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 12
- 239000007787 solid Substances 0.000 claims abstract description 9
- 230000009261 transgenic effect Effects 0.000 claims abstract description 9
- 230000004083 survival effect Effects 0.000 claims abstract description 8
- 230000007774 longterm Effects 0.000 claims abstract description 7
- 210000001124 body fluid Anatomy 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 239000010839 body fluid Substances 0.000 claims abstract description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 45
- 108010036949 Cyclosporine Proteins 0.000 claims description 45
- 229960001265 ciclosporin Drugs 0.000 claims description 36
- 229960000951 mycophenolic acid Drugs 0.000 claims description 33
- 229930182912 cyclosporin Natural products 0.000 claims description 31
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 23
- 210000000056 organ Anatomy 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 229960002930 sirolimus Drugs 0.000 claims description 20
- -1 MPA sodium salt Chemical class 0.000 claims description 19
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 18
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 17
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 3
- 230000000890 antigenic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 239000003085 diluting agent Substances 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 description 19
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 17
- 229930105110 Cyclosporin A Natural products 0.000 description 15
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 9
- 230000036765 blood level Effects 0.000 description 9
- 239000003018 immunosuppressive agent Substances 0.000 description 9
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 159000000000 sodium salts Chemical class 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 6
- 239000004530 micro-emulsion Substances 0.000 description 6
- 229940063121 neoral Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229960003444 immunosuppressant agent Drugs 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 238000011418 maintenance treatment Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011419 induction treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010063044 Ectopic kidney Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 101001062854 Rattus norvegicus Fatty acid-binding protein 5 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 150000002789 myriocins Chemical class 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9910835.9 | 1999-05-10 | ||
| GBGB9910835.9A GB9910835D0 (en) | 1999-05-10 | 1999-05-10 | Organic compounds |
| GBGB9925443.5A GB9925443D0 (en) | 1999-10-27 | 1999-10-27 | Organic compounds |
| GB9925443.5 | 1999-10-27 | ||
| PCT/EP2000/004250 WO2000067773A2 (en) | 1999-05-10 | 2000-05-10 | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002544167A true JP2002544167A (ja) | 2002-12-24 |
| JP2002544167A5 JP2002544167A5 (enExample) | 2006-01-05 |
Family
ID=26315533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000616798A Pending JP2002544167A (ja) | 1999-05-10 | 2000-05-10 | 有機化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20020132764A1 (enExample) |
| EP (2) | EP1980263A1 (enExample) |
| JP (1) | JP2002544167A (enExample) |
| AT (1) | ATE474590T1 (enExample) |
| AU (1) | AU4565000A (enExample) |
| DE (1) | DE60044717D1 (enExample) |
| WO (1) | WO2000067773A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522052A (ja) * | 2003-04-01 | 2006-09-28 | ノバルティス アクチエンゲゼルシャフト | ミコフェノール酸、その塩またはプロドラッグの非経腸製剤 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE222502T1 (de) * | 1996-07-30 | 2002-09-15 | Novartis Ag | Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält |
| ATE475418T1 (de) | 2000-01-14 | 2010-08-15 | Univ Pennsylvania | O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| BR112016006378A2 (pt) | 2013-09-24 | 2017-08-01 | Giner Inc | sistema para tratamento de gás de um implante de célula |
| WO2018093956A1 (en) | 2016-11-15 | 2018-05-24 | Giner, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
| JP7199632B2 (ja) | 2017-05-04 | 2023-01-06 | ガイナー，インク． | 堅牢なインプラント可能なガス送達装置ならびにそれを含む方法、システムおよび装置 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651968A (en) * | 1991-08-23 | 1997-07-29 | Alberta Research Council | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| WO1997035575A1 (en) * | 1996-03-27 | 1997-10-02 | Novartis Ag | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| WO1997038689A2 (en) * | 1996-04-12 | 1997-10-23 | Novartis Ag | Enteric-coated pharmaceutical compositions of mycophenolate |
| WO1998004279A1 (en) * | 1996-07-30 | 1998-02-05 | Novartis Ag | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178858A (en) * | 1987-12-02 | 1993-01-12 | Reichert Thomas A | Method for prevention of graft versus host disease |
| US5135934A (en) | 1990-07-06 | 1992-08-04 | Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| US5843452A (en) * | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| CA2190268C (en) | 1994-05-13 | 2000-01-25 | Wolfgang Bohm | Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood |
| US5624946A (en) * | 1994-07-05 | 1997-04-29 | Williams; James | Use of leflunomide to control and reverse chronic allograft rejection |
| IL115742A (en) | 1994-10-26 | 2000-06-01 | Novartis Ag | Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant |
| US5697109A (en) | 1994-10-28 | 1997-12-16 | Barton Medical Corporation | Patient transport system |
| US5631282A (en) * | 1995-06-07 | 1997-05-20 | Merck & Co., Inc. | Triterpenes |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| GB9619706D0 (en) | 1996-09-20 | 1996-11-06 | Pharmacia Spa | Synergistic immunosuppressant composition containing a 2,2'-bi-1H-pyrrole comp und |
| US5962415A (en) * | 1996-09-20 | 1999-10-05 | Bristol-Myers Squibb Co. | Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof |
| DE69835201T2 (de) | 1997-04-18 | 2007-06-14 | Novartis Ag | Neoglycoproteine |
| US6825395B1 (en) * | 1997-07-14 | 2004-11-30 | Nippon Meat Packers, Inc. | Transgenic non-human mammals expressing the human complement inhibitor (DAF/CD55) |
-
2000
- 2000-05-10 AT AT00927193T patent/ATE474590T1/de active
- 2000-05-10 AU AU45650/00A patent/AU4565000A/en not_active Abandoned
- 2000-05-10 DE DE60044717T patent/DE60044717D1/de not_active Expired - Lifetime
- 2000-05-10 EP EP08158054A patent/EP1980263A1/en not_active Withdrawn
- 2000-05-10 JP JP2000616798A patent/JP2002544167A/ja active Pending
- 2000-05-10 EP EP00927193A patent/EP1181034B1/en not_active Expired - Lifetime
- 2000-05-10 WO PCT/EP2000/004250 patent/WO2000067773A2/en not_active Ceased
-
2001
- 2001-11-07 US US10/035,663 patent/US20020132764A1/en not_active Abandoned
-
2005
- 2005-07-11 US US11/178,573 patent/US20050277585A1/en not_active Abandoned
-
2006
- 2006-11-15 US US11/599,814 patent/US20070060511A1/en not_active Abandoned
-
2008
- 2008-04-24 US US12/109,210 patent/US20080199478A1/en not_active Abandoned
-
2011
- 2011-02-11 US US13/025,347 patent/US8435520B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5651968A (en) * | 1991-08-23 | 1997-07-29 | Alberta Research Council | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| WO1997035575A1 (en) * | 1996-03-27 | 1997-10-02 | Novartis Ag | Use of rapamycin derivatives in vasculopathies and xenotransplantation |
| WO1997038689A2 (en) * | 1996-04-12 | 1997-10-23 | Novartis Ag | Enteric-coated pharmaceutical compositions of mycophenolate |
| WO1998004279A1 (en) * | 1996-07-30 | 1998-02-05 | Novartis Ag | Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006522052A (ja) * | 2003-04-01 | 2006-09-28 | ノバルティス アクチエンゲゼルシャフト | ミコフェノール酸、その塩またはプロドラッグの非経腸製剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000067773A3 (en) | 2001-06-28 |
| EP1181034B1 (en) | 2010-07-21 |
| DE60044717D1 (de) | 2010-09-02 |
| AU4565000A (en) | 2000-11-21 |
| US20050277585A1 (en) | 2005-12-15 |
| EP1980263A1 (en) | 2008-10-15 |
| US20110142953A1 (en) | 2011-06-16 |
| US20070060511A1 (en) | 2007-03-15 |
| US20080199478A1 (en) | 2008-08-21 |
| ATE474590T1 (de) | 2010-08-15 |
| WO2000067773A2 (en) | 2000-11-16 |
| EP1181034A2 (en) | 2002-02-27 |
| US8435520B2 (en) | 2013-05-07 |
| US20020132764A1 (en) | 2002-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8435520B2 (en) | Combinations of immunosuppressive agents for the treatment or prevention of graft rejections | |
| Nashan | Review of the proliferation inhibitor everolimus | |
| US12377054B2 (en) | Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis | |
| BRPI0708424A2 (pt) | prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento | |
| CN1293876C (zh) | 1，3－丙二醇衍生物的新用途 | |
| CA2481184A1 (en) | Medicament for preventing and/or treating chronic rejection | |
| Holtmeier et al. | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis | |
| US8507518B2 (en) | Method of treating mantle cell lymphoma | |
| Le Hello | The pharmacology and therapeutic aspects of colchicine | |
| JP2002544167A5 (enExample) | ||
| JP6878418B2 (ja) | 移植片拒絶反応の処置方法 | |
| ES2348077T3 (es) | Combinaciones de agentes inmunosupresores para el tratamiento o la prevención del rechazo de injertos. | |
| KR100681626B1 (ko) | 과다 반응성 염증 질환 및 자가면역질환의 치료를 위한 15-디옥시스페르구알린의 용도 | |
| US20240197816A1 (en) | Composition and method for prolong survival of transplant and recipient | |
| WO2005055997A1 (ja) | 炎症性疾患の治療及び予防用医薬組成物 | |
| AU2020381064A1 (en) | Use of compound in preventing or treating graft versus host disease | |
| Fasola et al. | DACLIZUMAB (DZB) INDUCTION IN ADULT HEPATITIS C (HCV) LIVER TRANSPLANT RECIPIENTS (OLT): A SINGLE CENTER EXPERIENCE WITH DIFFERENT ANTIBODY DOSES.: 176 | |
| Abdelaziz et al. | TACROLIMUS (FK 506) TOXICITY IN THE EARLY POSTOPERATIVE PERIOD FOLLOWING LIVING DONOR LIVER TRANSPLANTATION (LDLT) AMONG EGYPTIAN ADULTS: LIMITED EXPERIANCE.: 175 | |
| Kirimlioglu et al. | LIVER PATHOLOLOGY AND CELL PROLIFERATION AFTER CALCINEURIN INHIBITORS AND ANTIPROLIFERATIVE DRUGS FOLLOWING PARTIAL HEPATECTOMY IN RAT.: 174 | |
| Lorf et al. | PRIMARY SIROLIMUS BASED IMMUNOSUPPRESSION ALLOWS DELAYED USE OF CNI IN LIVER TRANSPLANTATION.: 173 | |
| HK1120444B (en) | Prolongation of survival of an allograft by inhibiting complement activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050803 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090121 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090121 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090318 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090421 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090424 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091229 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100108 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100212 |